01—Abstract
Summary
Summary of the 8-K filed February 18, 2026. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. announced on February 18, 2026 that it has appointed Glenn Coleman as Corporate Executive Vice President and Chief Financial Officer, with a tentative start date of April 6, 2026.
Mr. Coleman, 58, most recently served since 2024 as Chief Financial Officer and Chief Administrative Officer of Premier, Inc., described in the filing as a $1a-billion healthcare services business. His earlier roles include CFO of DENTSPLY SIRONA Inc. and Integra Life Sciences Holdings Corporation, where he also served as Executive Vice President and Chief Operating Officer from 2019 to 2022. He succeeds Michael G.
Knell, who has served as interim CFO since September 2025 and will remain Corporate Senior Vice President and Chief Accounting Officer. The filing describes an at-will employment offer letter dated February 12, 2026, with the following material terms: a base salary of $800,000b annually, a 2026 target bonus of 85% of base salary (pro-rated to his hire date), a 2026 equity award with a grant value of $3,000,000 (60% performance share units and 40% restricted stock units) beginning in May 2026, a one-time new hire cash award of $1,875,000, and a one-time new hire restricted stock unit award with a grant value of $3,500,000 vesting 25% annually over four years.
The full offer letter is filed as Exhibit 10.1. The filing states there are no family relationships between Mr. Coleman and any director or executive officer, and no related-person transactions requiring disclosure under Item 404(a) of Regulation S-K.
02—Key points
Key Highlights
- Glenn Coleman appointed Corporate Executive Vice President and Chief Financial Officer, with a tentative start date of April 6, 2026
- Coleman succeeds Michael G. Knell, who has been interim CFO since September 2025 and will continue as Corporate Senior Vice President and Chief Accounting Officer
- Base salary set at $800,000 annually, with a 2026 target bonus of 85% of base salary, pro-rated to the hire date
- 2026 annual equity award with a grant value of $3,000,000, comprised of 60% performance share units and 40% restricted stock units, beginning May 2026
- One-time new hire cash award of $1,875,000: $1,000,000 paid six months after start date and $875,000 paid after 12 months of employment
- One-time new hire RSU award with a grant value of $3,500,000, vesting 25% annually over four years
- Coleman's background includes CFO roles at DENTSPLY SIRONA Inc. and Integra Life Sciences Holdings Corporation and most recently CFO and Chief Administrative Officer of Premier, Inc.
03—Questions
Frequently Asked Questions
Who is the new Chief Financial Officer and when does he start?
Glenn Coleman, 58, was appointed Corporate Executive Vice President and Chief Financial Officer. His tentative start date is April 6, 2026.
What happens to the current interim CFO?
Michael G. Knell, who assumed the interim CFO role in September 2025, will continue in his current role as Corporate Senior Vice President and Chief Accounting Officer.
What is Coleman's compensation package?
The offer letter provides a base salary of $800,000 annually; a 2026 target bonus of 85% of base salary, pro-rated to his hire date; a 2026 equity award with a grant value of $3,000,000 (60% PSUs and 40% RSUs) beginning in May 2026; a one-time new hire cash award of $1,875,000; and a one-time new hire RSU award with a grant value of $3,500,000 vesting 25% annually over four years.
What is Coleman's relevant experience?
The filing states he has more than 30 years of financial and operational management experience, including since 2024 as CFO and Chief Administrative Officer of Premier, Inc.; as CFO of DENTSPLY SIRONA Inc. and Integra Life Sciences Holdings Corporation; and as Executive Vice President and Chief Operating Officer of Integra from 2019 to 2022. He is a Certified Public Accountant.
Are there any related-party relationships or transactions disclosed?
The filing states there are no family relationships between Mr. Coleman and any director or executive officer of the Company, and no transactions involving the Company that would be required to be reported under Item 404(a) of Regulation S-K.
04—Continue